摘要
<p><b>OBJECTIVES</b>To investigate the reversal effect of gene MDR1 and MRP with combinational antisense phosphorothioate oligonucleotide on Drug-resistant human hepatocellular carcinoma cells SMMC-7721/ADM.</p><p><b>METHODS</b>SMMC-7721/ADM was transfected with synthetic antisense phosphorothioate oligonucleotides complementary to gene MDR1 and MRP mediated by Lipofectamine. Drug sensitivity was measured by MTT assay, Fluorescence intensity of cells was determined by flow cytometric analysis, RH123 and DNR retention was assayed by confocal scanning laser microscopy.</p><p><b>RESULTS</b>ASODN of MDR1+MRP increased the sensitivity of SMMC-7721/ADM to chemotherapeutic drug more significantly than that any of MDR1 and MRP did separately. But they did not enhance the inhibition expression of protein of p190 or p170.</p><p><b>CONCLUSION</b>Drug-resistance could be reversed significantly when antisense phosphorothioate oligonucleotide of MDR1+MRP were transfected into drug-resistant human hepatocellular carcinoma cells SMMC-7721/ADM together.</p>
Subject(s)
Humans , Carcinoma, Hepatocellular , Drug Therapy , Genetics , Cell Line, Tumor , Daunorubicin , Metabolism , Pharmacology , Doxorubicin , Pharmacology , Drug Resistance, Neoplasm , Genes, MDR , Liver Neoplasms , Drug Therapy , Genetics , Multidrug Resistance-Associated Proteins , Genetics , Oligonucleotides, Antisense , Pharmacology , Rhodamine 123 , Metabolism摘要
<p><b>OBJECTIVE</b>To investigate the alteration of HBV markers in liver allograft of HBV related recipients pre and post liver transplantation under Lamivudine or combination of Lamivudine with HBIG prophylaxis and explore the mechanism of HBV de nova infection in liver allograft after orthotopic liver transplantation, as well as seek to establish a optimal prophylactic protocol.</p><p><b>METHODS</b>The serial liver biopsy specimens of 90 liver allograft and sera of 78 liver transplant recipients during operation and after 1 week, 1 month, 3 months, 6 months, 12 months, 24 months post transplantation have been collected and detected for HBV markers with enzyme-linked radioimmunoassay, fluorescent quantitative assay for HBV-DNA in serology and with immunohistochemistry stain, HBV-DNA in situ hybridization in histology for detection of HBV markers in liver allograft samples.</p><p><b>RESULTS</b>Whether recipients with active replicative or inactive replicative HBV preoperatively, none of positive HBV-DNA, HBsAg and HBcAg in 100% liver biopsy specimens with HBV-DNA hybridization in situ and immunohistochemistry stains in histology within 2 hours after reperfusion.</p><p><b>CONCLUSION</b>Whatever HBV replicative status the recipients have before surgery, no evidence of HBV particles direct invasion to the liver allograft from HBV related cirrhotics during operation under current prophylactic measures. However, the further supposed mechanism and its significance in HBV de nova infection of liver allograft remained to be disclosed further.</p>
Subject(s)
Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Biomarkers , Blood , DNA, Viral , Blood , Hepatitis B Antigens , Blood , Hepatitis B Surface Antigens , Blood , Hepatitis B e Antigens , Blood , Hepatitis B virus , Genetics , Hepatitis B, Chronic , Diagnosis , Drug Therapy , General Surgery , Immunization, Passive , Immunoglobulins , Lamivudine , Therapeutic Uses , Liver Transplantation , Preoperative Care , Methods , Secondary Prevention摘要
<p><b>OBJECTIVE</b>To assess the diagnosis and treatment of invasive lung aspergillosis after liver transplantation.</p><p><b>METHODS</b>Routine sputum culture was performed. Itraconazole and fluconazole were used to prevent fungal infection prophylactically. Amphyotericin B was only used on aspergillosis. In 54 patients receiving, liver transplantation, 3 patients with lung aspergillosis were reviewed.</p><p><b>RESULTS</b>Of the 3 patients 2 died and 1 recovered.</p><p><b>CONCLUSIONS</b>Over-immunosuppression is a main risk factor for aspergillosis. Amphotericin B is still the best choice for the treatment of aspergillosis and its gradual, interrupted, low concentration administration, cooperated with itraconazole can ease the side effects.</p>